Instituto de Investigaciones Biomédicas de Madrid - CSIC

What Instituto de Investigaciones Biomédicas de Madrid - CSIC does

The Instituto de Investigaciones Biomédicas Sols-Morreale (IIBM) is a joint research center of Spain's Consejo Superior de Investigaciones Científicas (CSIC) and the Universidad Autónoma de Madrid (UAM), headquartered at C/ Arturo Duperier 4, Madrid. It operates as a public research institution with approximately 210 employees, conducting translational biomedical research on the molecular basis of human pathology across four departments: Cancer (18 groups), Metabolic and Immune Diseases (12 groups), Neurological Diseases and Aging (12 groups), and Rare Diseases (10 groups). The institute employs molecular biology, cellular biology, genetics, computational biology, and preclinical imaging (including unique MRI-PET equipment) alongside model organisms such as mice, Drosophila, yeast, and Dictyostelium.

IIBM delivers research programs, scientific-technical services, the proprietary ENNI (Non-Invasive Neurofunctional Evaluation) service, Biocomp Tools bioinformatics resources, and training seminars. Researchers are organized into more than 50 specialized groups covering topics such as auditory neurobiology, oncology, mitochondrial disease, autophagy, and rare diseases including BPAN, ChAc, and Joubert syndrome. Core technical differentiators include the ENNI service, unique MRI-PET preclinical imaging capability, and disease-specific animal/cellular models. The institute collaborates clinically with Hospital Universitario La Paz and UCM, participates in CIBERONC and CIBERER-ISCIII networks, and engages internationally through the WHO World Hearing Forum.

IIBM does not operate a commercial revenue model. It is funded by public grants from the Ministerio de Ciencia, Innovación y Universidades, the Agencia Estatal de Investigación (AEI), Instituto de Salud Carlos III (ISCIII), Comunidad de Madrid, and EU programs (Next Generation EU, FEDER, Fondo Social Europeo). Outputs are distributed through peer-reviewed publications, clinical collaborations, scientific-technical services, and the Refoxy Pharma spin-off technology transfer. The institute holds ISO 9001 (certificate 55790) and IQNet quality certifications.

Name

Instituto de Investigaciones Biomédicas de Madrid - CSIC

Legal name

Instituto de Investigaciones Biomédicas Sols-Morreale

Website

https://iib.uam.es

Company type

Private

Operating status

Operating

Headcount range

101–250 employees

Short description

The Instituto de Investigaciones Biomédicas Sols-Morreale (IIBM) is a joint public research center of CSIC and Universidad Autónoma de Madrid, conducting translational biomedical research across cancer, metabolic, neurological, and rare diseases through 50+ specialized research groups in Madrid, Spain.

Ownership category

akta.pro rank

Product category

Biomedical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYEDAHAGAI

Biomedical Sciences & Medical Research Institutes (University-Based)

Education/Higher Education (Colleges & Universities)/Medical & Health Sciences Universities

SECONDARYHLAFAMAL

Clinical Research & Trial Central Laboratories

Healthcare & Life Sciences/Healthcare Providers & Systems/Clinical Laboratories

SECONDARYHLAAAMAB

Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy)

Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

• Biomedical research services
• Translational medicine research
• Preclinical imaging studies
• Rare disease research
• Cancer research programs

Headquarters

HQ city

Madrid

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations

Distribution channels3 records

Marketing channels4 records

Core offering

IIBM conducts basic and clinical biomedical research with a translational approach across four departments (Cancer; Metabolic and Immune Diseases; Neurological Diseases and Aging; Rare Diseases). It sells scientific-technical laboratory services, the proprietary ENNI non-invasive neurofunctional evaluation service, and bioinformatics tools, while operating as a public research institute rather than a commercial product vendor.

Product overview

The Instituto de Investigaciones Biomédicas Sols-Morreale (IIBM) is a joint research center of CSIC and Universidad Autónoma de Madrid focused on studying the molecular basis of human pathology with a translational approach. The institute operates through four main research departments (Cancer; Metabolic and Immune Diseases; Neurological Diseases and Aging; Rare Diseases), each containing multiple specialized research groups. The portfolio includes proprietary technology services like the ENNI (Non-Invasive Neurofunctional Evaluation) service for neurofunctional assessment, scientific-technical laboratory services, bioinformatics tools, and educational seminar programs. Research integrates basic and clinical investigation to advance diagnostic and therapeutic strategies.

Differentiator

Problem solved

Functional benefit

Products and services

• IIBM Research Programs
• ENNI (Non-Invasive Neurofunctional Evaluation) Service
• Scientific-Technical Laboratory Services
• Biocomp Tools
• Seminars and Training Programs

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Consejo Superior de Investigaciones Científicas (CSIC)coreStrategic or Co-development PartnerCSIC is the main institutional partner, co-founding IIBM as a joint center. CSIC provides funding, administrative support, and research infrastructure to the institute.
• Universidad Autónoma de Madrid (UAM)coreStrategic or Co-development PartnerUAM is the co-founding university partner, jointly operating IIBM as a joint center with CSIC. Provides academic affiliation and research collaboration opportunities.
• Hospital Universitario La PazcoreStrategic or Co-development PartnerClose collaboration with the Otorhinolaryngology Department of La Paz University Hospital has been key to achieving ambitious scientific goals and consolidating international leadership in auditory neurobiology research.
• Universidad Complutense de Madrid (UCM)coreStrategic or Co-development PartnerMultidisciplinary collaboration with Faculty of Veterinary Medicine and Faculty of Medicine of UCM, integrating faculty members into the auditory neurobiology research group.
• CIBERONCcoreStrategic or Co-development PartnerBiomedical Research Networking Centre on Cancer - IIBM researcher Gema Moreno Bueno serves as Scientific Director of CIBERONC.
• CIBERER-ISCIIIcoreStrategic or Co-development PartnerBiomedical Research Networking Centre on Rare Diseases - supports rare disease research at IIBM including hearing loss and myelinopathies research.
• World Health Organization (WHO)minorStrategic or Co-development PartnerIIBM researchers participate in WHO World Hearing Forum, representing the institute in international health policy discussions on hearing health.
• Refoxy PharmaminorStrategic or Co-development PartnerIIBM spin-off company founded by researcher Wolfgang Link, recognized by CSIC for successful technology transfer from academic research.
• Various Health InstitutionscoreStrategic or Co-development PartnerClinical groups from different Health Institutions collaborate with IIBM on research projects, development of functional and genetic tests, and search for new treatments for rare diseases.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Max Planck Institute for Biology of Ageing: German Max Planck Society research institute focused on molecular and cellular biology of ageing and disease. Comparable to IIBM as a publicly funded, model-organism-driven translational research institute with overlapping research areas (ageing, metabolic disease).
• Centro de Investigaciones Biológicas Margarita Salas (CIB-CSIC): Another CSIC-affiliated biological research centre in Madrid covering molecular biology, microbiology, and biomedicine. Comparable to IIBM in governance (shared CSIC parent), scope, and Madrid-based public research mission.
• Institut de Recerca Biomèdica (IRB Barcelona): Catalan biomedical research centre studying the molecular basis of disease including cancer, metabolism, and rare diseases. Closely comparable to IIBM in mission, research scope, and translational orientation.
• Centro de Regulación Genómica (CRG): Barcelona-based biomedical research institute focused on gene regulation, molecular biology, and computational biology. Comparable to IIBM as a publicly funded translational research centre with cross-cutting disease research programs and similar scale and operating model.
• Centro Nacional de Biotecnología (CNB-CSIC): CSIC's national biotechnology research centre, sharing IIBM's parent institution (CSIC). Strong peer on dimensions of basic-to-translational biotech research, model organism work, and public-sector research governance.
• Centro Nacional de Investigaciones Oncológicas (CNIO): Spain's national cancer research centre, also under public governance. Highly comparable to IIBM as a translational biomedical research institute with oncology focus, government funding, and a national consortium mandate — overlapping with IIBM's cancer department and CIBERONC participation.

Broad incumbents

• Institut Pasteur: Historic French biomedical research institute covering infectious disease, developmental biology, and neuroscience. Comparable to IIBM as a publicly funded multidisciplinary biomedical research institute with translational outputs and proprietary service offerings.
• Broad Institute: Joint MIT/Harvard genomics and biomedical research institute. Comparable to IIBM in applying computational biology, genomics, and molecular biology to disease research, though at much larger scale and with deeper industry partnerships.
• Francis Crick Institute: One of Europe's largest biomedical research institutes, covering cancer, neuroscience, and infectious disease. Comparable to IIBM in mission and translational research scope, though at substantially larger scale and with broader funding sources.
• Karolinska Institutet: Sweden's medical university with extensive biomedical research programs across cancer, neuroscience, and rare diseases. Comparable to IIBM as a public-sector university-affiliated translational research enterprise, though operating at significantly larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCYanykLgCm8aGOT9dbTlNWg
• LinkedInlinkedin.com/company/instituto-de-investigaciones-biom-dicas-de-madrid---csic

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Instituto de Investigaciones Biomédicas de Madrid - CSIC